Clinical trial NCT03725059 is currently recruiting patients in Brazil and Colombia to test neoadjuvant chemotherapy in combination with Pembrolizumab in early stage ER positive, HER2 negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.